FDA APPROVES THIRD ONCOLOGY DRUG THAT TARGETS A KEY GENETIC DRIVER OF CANCER, RATHER THAN A SPECIFIC TYPE OF TUMOR.
The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib), a treatment for adult and adolescent patients whose cancers have the specific genetic defect, NTRK (neurotrophic tyrosine receptor kinase) gene fusion and for whom there are no effective treatments. This is the third time the agency has approved a cancer treatment based […]
